Karessa Pharma Holding AB (publ) Stock price

Equities

KARE

SE0005506193

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Stockholm 5-day change 1st Jan Change
- SEK -.--% Intraday chart for Karessa Pharma Holding AB (publ) -14.69% -26.06%
Sales 2017 - Sales 2018 0.22 2.3 Capitalization 54.34M 580M
Net income 2017 -47M -502M Net income 2018 -24M -256M EV / Sales 2017 -
Net cash position 2017 39.5M 422M Net cash position 2018 26.66M 285M EV / Sales 2018 128,762,791 x
P/E ratio 2017
-2.36 x
P/E ratio 2018
-2.2 x
Employees -
Yield 2017 *
-
Yield 2018
-
Free-Float 99%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 77 17-12-31
Chief Tech/Sci/R&D Officer 68 14-12-31
Director/Board Member 61 19-10-21
Members of the board TitleAgeSince
Director/Board Member 61 19-10-21
Founder 55 13-09-10
Director/Board Member 72 13-12-31
More insiders
Karessa Pharma Holding AB (publ) is a Sweden-based pharmaceutical company with the goal of developing products based on a patented drug delivery platform with direct absorption of active substances from the oral cavity to the bloodstream. The drug delivery platform is in the form of buccal film, an alignate-based polymer film, which is applied to the oral mucosa and through it the drug is then rapidly delivered into the bloodstream, while the film dissolves without leaving any residues in the mouth. The Company's research and development projects are based on active substances that have already been approved for use as medicinal products in other forms, and include, among others, Karessa k03 vardenafil via buccal film for the treatment of erectile dysfunction and Karessa k21 midazolam via buccal film for the treatment of anxiety and epilepsy symptoms.
More about the company
  1. Stock
  2. Equities
  3. Stock Karessa Pharma Holding AB (publ) - Nasdaq Stockholm